Clinical trial
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00085488 · Dartmouth-Hitchcock Medical Center, Other · Completed
Key facts
| NCT number | NCT00085488 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma |
| Official title | En Vivo Matured Dendritic Cell Therapy in Patients With Melanoma |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | autologous tumor cell vaccine, therapeutic autologous dendritic cells |
| Start date | Feb 1, 2004 |
| Primary completion | Feb 1, 2006 |
| Completion | Feb 1, 2006 |
| First posted | Jun 11, 2004 |
| Last update posted | Feb 2, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: